Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
17.12
-0.08 (-0.47%)
Jun 8, 2026, 4:00 PM EDT - Market closed
AAPG Revenue
In the year 2025, Ascentage Pharma Group International had annual revenue of 574.12M CNY, down -41.46%. Ascentage Pharma Group International had revenue of 340.42M in the half year ending December 31, 2025, with 329.37% growth.
Revenue (ttm)
574.12M CNY
Revenue Growth
-41.46%
P/S Ratio
19.35
Revenue / Employee
748,527 CNY
Employees
767
Market Cap
1.59B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 574.12M | -406.53M | -41.46% |
| Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
| Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
| Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
| Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
| Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
| Dec 31, 2019 | 14.51M | 7.71M | 113.21% |
| Dec 31, 2018 | 6.81M | 479.00K | 7.57% |
| Dec 31, 2017 | 6.33M | -1.34M | -17.46% |
| Dec 31, 2016 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Sarepta Therapeutics | 2.18B |
| Innoviva | 420.69M |
| AbCellera Biologics | 79.21M |
| Nurix Therapeutics | 71.78M |
| Agios Pharmaceuticals | 66.05M |
| Generate Biomedicines | 30.30M |
| Capricor Therapeutics | 11.13M |
AAPG News
- 7 days ago - Ascentage Pharma presents data on olverembatinib - TheFly
- 7 days ago - Ascentage Pharma presents data from Phase 1b study of olverembatinib - TheFly
- 7 days ago - Ascentage Pharma presents first dataset of alrizomadlin - TheFly
- 7 days ago - Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 - GlobeNewsWire
- 7 days ago - Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 - GlobeNewsWire
- 7 days ago - Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 - GlobeNewsWire
- 17 days ago - Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 - GlobeNewsWire
- 26 days ago - Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress - GlobeNewsWire